PROKARIUM
7.2.2024 13:01:36 CET | Business Wire | Press release
Prokarium, a clinical-stage biopharmaceutical company bioengineering Living Cures through cutting-edge synthetic biology, today announces the dosing of the first patient in their PARADIGM-1 Phase I/Ib clinical trial in non-muscle invasive bladder cancer (NMIBC) patients (NCT06181266).
The study is being conducted at multiple clinical sites across the United States and will initially evaluate the safety of a single intravesical administration of their investigational immunotherapy, ZH9, in NMIBC patients. The study will further investigate and characterize clinical efficacy of the ZH9 treatment regimen in pre-planned expansion cohorts under the same IND.
“Dosing our first patient in the clinical trial is an exciting milestone,” said Dr. Josefin-Beate (Josi) Holz, CMO of Prokarium. “It translates our scientific promises into practical advancements, as we strive to transform the treatment paradigm for patients with NMIBC.”
Dr. Daniel Zainfeld, Urology San Antonio, commented, “We are excited to have dosed our first patient in Prokarium’s PARADIGM-1 study. The trial provides us the opportunity to explore an innovative treatment approach for our NMIBC patients who are facing significant gaps in available effective treatment options.”
Kristen Albright, CEO of Prokarium, remarked, "We are grateful to the patients and urologists involved in the PARADIGM-1 clinical trial. This achievement represents a pivotal moment for Prokarium as we introduce Living Cures, a novel class of immunotherapies built with synthetic biology.”
About Prokarium
Prokarium is a clinical-stage biopharmaceutical company bioengineering Living Cures through cutting-edge synthetic biology. Prokarium’s lead program, currently advancing in US clinical trials for bladder cancer, is a single-dose therapy redesigning the treatment paradigm for patients. The Company’s Living Cures platform aims to transform precision medicine into off-the-shelf programmable therapeutics, promising a new class of immunotherapies with a goal of equitable access. Prokarium is based in London, UK. For further information, visit https://www.prokarium.com.
About ZH9
ZH9, a proprietary bacterial immunotherapy under investigation in the PARADIGM-1 clinical trial (NCT06181266) in the United States, seeks to redesign the treatment paradigm for non-muscle invasive bladder cancer patients through a single-dose intravesical induction regimen.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240207504370/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FuriosaAI Secures $620 Million Series D to Meet Surging Enterprise AI Inference Demand and Accelerate Next-Gen Silicon29.10.2026 00:57:00 CET | Press release
Global investors, including Infinitum, Jericho Capital, QUDA Capital, Cisco Investments, and Worldline Capital, join the round alongside the National Growth Fund of Korea and Korean institutions. FuriosaAI, an AI semiconductor company building sustainable, high-performance inference compute for data centers, today announced the completion of its $620 million (KRW 820 billion) Series D round, bringing its post-money valuation to approximately $2.9 billion. The financing marks a major milestone as FuriosaAI scales global commercial deployments of its RNGD AI inference accelerator. FuriosaAI will use the new capital to expand RNGD production, strengthen its software ecosystem, and accelerate development of its third-generation AI accelerator. International investors contributed a total of $110 million to the round, bringing deep expertise across AI semiconductors and computing infrastructure. U.S.-based Infinitum, an investment firm with extensive experience in the AI semiconductor sector
IFF Declares Dividend for Fourth Quarter 202628.10.2026 21:15:00 CET | Press release
IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on January 13, 2027 to shareholders of record as of December 19, 2026. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, and health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2026 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20261028159928/en/
Andersen Consulting indgår samarbejde med JKIT28.10.2026 19:57:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital og forretningsmæssig transformation gennem en samarbejdsaftale med John Keells IT (JKIT), en udbyder af teknologiløsninger med base i Sri Lanka. JKIT leverer teknologirådgivning og digitale transformationstjenester til organisationer på tværs af flere brancher, herunder luftfart, finansielle tjenesteydelser, sundhedsvæsen, produktion, detailhandel og telekommunikation. Virksomhedens kompetencer spænder over forretningskritiske applikationer, cloudtransformation, cybersikkerhed, data og analyse, kunstig intelligens samt intelligent automatisering. Gennm strategiske partnerskaber med førende teknologiudbydere som SAP, Microsoft, Salesforce, Databricks og AWS hjælper JKIT organisationer med at modernisere deres teknologiske infrastruktur, effektivisere driften, styrke beslutningsgrundlaget og skabe vækst i forretningen. "Organisationer ønsker i dag at fremskynde deres digitale transformation og ai-tilpasning og har brug for ko
Transition Industries Signs Definitive EPC Agreement with Siemens Energy and Techint E&C for Pacifico Mexinol’s 210 MW Electrolyzer Facility28.10.2026 19:36:00 CET | Press release
Definitive agreement advances delivery of the electrolyzer facility supplying renewable hydrogen for ultra-low-carbon methanol production in Sinaloa, Mexico Transition Industries LLC today announced that it has signed a definitive Engineering, Procurement and Construction (EPC) agreement with Siemens Energy and Techint Engineering & Construction (“Techint E&C”) for the approximately 210 MW electrolyzer facility at its Pacifico Mexinol project in Sinaloa, Mexico. The agreement is subject to customary conditions precedent, including the completion of project financing. The signing builds on the Front-End Engineering Design (FEED) contract announced in August 2025 and represents an important milestone in advancing the project’s renewable hydrogen production infrastructure from engineering toward construction. The facility will incorporate Siemens Energy’s Elyzer P-300 electrolyzer technology and produce renewable hydrogen to support the production of renewable fuels of non-biological orig
Belkin Introduces Infinity Folio for iPad mini, Available Now28.10.2026 19:21:00 CET | Press release
With a precision-engineered hinge that allows flexible viewing angles, all-around drop protection, and a frosted translucent back panel, Infinity Folio is the perfect companion for iPad mini from day one Belkin, a global leader in consumer electronics accessories trusted by more than 1 billion customers worldwide, today introduced Infinity Folio, a beautifully crafted protective case exclusively designed for iPad mini. The Infinity Folio is engineered to protect without compromise. A thin, lightweight and translucent back lets the new iPad mini design shine through with 360° of protection against drops of up to 2 meters*. The ingeniously engineered detachable cover transforms into a stand with multiple viewing angles. Whether it's streaming a favorite show, joining a video call, or reading an exciting book, Infinity Folio adapts to every moment. Designed specifically for iPad mini, Infinity Folio is available at launch through Apple stores and online in select markets worldwide, with a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom